NEW YORK, NY / ACCESS Newswire / March 6, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

CStone Pharmaceuticals ("CStone", HKEX: 2616), a biopharmaceutical company dedicated to developing innovative cancer therapies, today announced the submission of a Phase Ib clinical trial application ...

Foresight Diagnostics and the University of Washington School of Medicine and Fred Hutch Cancer Center have announced the ...

The first patient has been dosed with EVM16 at Peking University Cancer Hospital, marking a major milestone as Everest's proprietary AI-based tumor neoantigen prediction algorithm ...

Oppenheimer Asset Management Inc. lessened its stake in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX – Free Report) by 6.2% in ...

A phase 1/2 trial is evaluating HLD-0915, a novel oral therapy, for metastatic castration-resistant prostate cancer in up to ...

Phase 1 Dose Expansion Initiated for FT819 Off-the-Shelf CAR T-cell Product Candidate with Fludarabine-free Conditioning in Moderate-to-Severe ...

Antengene’s Xpovio approved for commercialization in Indonesia: Shanghai Thursday, March 6, 2025, 12:00 Hrs [IST] Antengene Corporation Limited, a leading innovative, commercial ...

Drugs in late-stage development may mean competition on price for two Pfizer medications that, by some accounts, are the most expensive cardiac medications in history.

Vutrisiran treatment reduced the risk of death and recurrent cardiovascular events compared to placebo in patients with ...

The acquisition is expected to enhance Jazz's oncology portfolio by adding dordaviprone, a novel small molecule therapy in ...

Q4 2024 Earnings Call Transcript March 4, 2025 Compugen Ltd. misses on earnings expectations. Reported EPS is $-0.07 EPS, ...